Pharmacokinetic evaluation of ibrexafungerp for the treatment of vulvovaginal candidiasis and beyond.
Expert Opin Drug Metab Toxicol
; 20(8): 713-718, 2024 Aug.
Article
in En
| MEDLINE
| ID: mdl-38957078
ABSTRACT
INTRODUCTION:
Ibrexafungerp is a new triterpenoid antifungal agent with activity against a variety of fungal species, including Aspergillus spp. and echinocandin-resistant Candida spp. AREAS COVERED This evaluation will summarize currently available clinical evidence on the use of ibrexafungerp in the treatment/prevention of vulvovaginal candidiasis (VVC) and detail the mechanism of action, pharmacokinetic/pharmacodynamic parameters, and ongoing/latest research involving ibrexafungerp. EXPERT OPINION The evidence involving the utilization of ibrexafungerp for the treatment of VVC shows that it is superior when compared to placebo and has comparable clinical cure rates when compared with fluconazole. Ibrexafungerp demonstrates reliable coverage against several Candida spp. including echinocandin-resistant strains, Candida auris, and Aspergillus spp. For VVC, a dose of 300 mg (two 150 mg tablets) twice daily is recommended and does not require dose adjustments based on renal or hepatic function. The use of ibrexafungerp outside of VVC is currently under study with several ongoing trials showing promising interim data.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Triterpenes
/
Candida
/
Candidiasis, Vulvovaginal
/
Drug Resistance, Fungal
/
Antifungal Agents
Limits:
Animals
/
Female
/
Humans
Language:
En
Journal:
Expert Opin Drug Metab Toxicol
Journal subject:
METABOLISMO
/
TOXICOLOGIA
Year:
2024
Document type:
Article
Affiliation country:
Country of publication: